Cynthia Anderson
Emory University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Cynthia Anderson.
Cancer Research | 2006
Shian Ying Sung; Hiroyuki Kubo; Katsumi Shigemura; Rebecca S. Arnold; Sanjay Logani; Ruoxiang Wang; Hiroyuki Konaka; Masayuki Nakagawa; Spiro Mousses; Mahul B. Amin; Cynthia Anderson; Peter A.S. Johnstone; John A. Petros; Fray F. Marshall; Haiyen E. Zhau; Leland W.K. Chung
The ADAM (a disintegrin and metalloprotease) family is a group of transmembrane proteins containing cell adhesive and proteolytic functional domains. Microarray analysis detected elevated ADAM9 during the transition of human LNCaP prostate cancer cells from an androgen-dependent to an androgen-independent and metastatic state. Using a prostate tissue array (N = 200), the levels of ADAM9 protein expression were also elevated in malignant as compared with benign prostate tissues. ADAM9 protein expression was found in 43% of benign glands with light staining and 87% of malignant glands with increasing intensity of staining. We found that ADAM9 mRNA and protein expressions were elevated on exposure of human prostate cancer cells to stress conditions such as cell crowding, hypoxia, and hydrogen peroxide. We uncovered an ADAM9-like protein, which is predominantly induced together with the ADAM9 protein by a brief exposure of prostate cancer cells to hydrogen peroxide. Induction of ADAM9 protein in LNCaP or C4-2 cells can be completely abrogated by the administration of an antioxidant, ebselen, or genetic transfer of a hydrogen peroxide degradative enzyme, catalase, suggesting that reactive oxygen species (ROS) are a common mediator. The induction of ADAM9 by stress can be inhibited by both actinomycin D and cycloheximide through increased gene transcription and protein synthesis. In conclusion, intracellular ROS and/or hydrogen peroxide, generated by cell stress, regulate ADAM9 expression. ADAM9 could be responsible for supporting prostate cancer cell survival and progression. By decreasing ADAM9 expression, we observed apoptotic cell death in prostate cancer cells.
The Prostate | 2011
Sajni Josson; Cynthia Anderson; Shian Ying Sung; Peter A.S. Johnstone; Hiroyuki Kubo; Chia Ling Hsieh; Rebecca S. Arnold; Murali Gururajan; Clayton Yates; Leland W.K. Chung
Recent studies demonstrated the importance of ADAM9 in prostate cancer relapse upon therapy. In this study, we determined the role of ADAM9 in the therapeutic resistance to radiation and chemotherapy.
Seminars in Radiation Oncology | 2010
Cynthia Anderson; Walter J. Curran
With 40,000 to 50,000 patients diagnosed annually, stage III lung cancer represents approximately one third of all non-small-cell lung cancer cases. It is a heterogeneous disease stage encompassing stage IIIa, for which surgery in combination with chemotherapy and/or radiation therapy represents a treatment strategy for select patients, and stage IIIb, for which chemoradiation represents the prevailing standard of care. Overcoming unacceptably high rates of intrathoracic tumor failures remains a central obstacle. Current clinical trial efforts focus on targeted therapies, new chemotherapy regimens, dose-escalated radiation therapy, and improvements in radiation therapy treatment delivery.
International Journal of Radiation Oncology Biology Physics | 2012
Shannon Kahn; Ashesh B. Jani; Scott Edelman; Peter J. Rossi; Karen D. Godette; Jerome C. Landry; Cynthia Anderson
PURPOSE To compare the biochemical outcome and toxicity scores of men with human immunodeficiency virus (HIV) and prostate cancer with a matched control population with negative or unknown HIV status when treated with external-beam radiotherapy (EBRT). METHODS AND MATERIALS A single-institution database of men with prostate cancer treated with EBRT from 1999 to 2009 was reviewed. Thirteen men with HIV were identified and matched to 2 control patients according to age, race, T stage, prostate-specific antigen level, Gleason score, RT dose, intensity-modulated RT vs. three-dimensional conformal RT, and whole-pelvis vs. prostate-only RT, for a total of 39 cases. The median follow-up time was 39 months (range, 3-110 months). RESULTS The 4-year biochemical failure (BF)-free survival rate was 87% in the HIV-positive group vs. 89% in the controls (p = 0.94). Pre- and post-RT viral loads were found to be predictive of BF (p = 0.04 and p = 0.04, respectively). No men with HIV died, whereas 2 in the control group died of causes unrelated to prostate cancer. Acute and chronic genitourinary and gastrointestinal toxicity were less in the HIV-positive patients than in controls (p < 0.001, p < 0.001, p = 0.003, and p < 0.001, respectively). The HIV-positive men experienced an average decline in CD4 count of 193 cells/mm(3). CONCLUSIONS Our findings suggest that men with HIV treated with EBRT have a similar risk of BF; however, high viral loads may contribute to an increased risk. This analysis supports that HIV-positive men with prostate cancer can be treated with definitive EBRT with similar disease control and toxicity outcomes as in the general population.
Clinical Genitourinary Cancer | 2006
Leland W.K. Chung; Wen Chin Huang; Shian Ying Sung; Daqing Wu; Valerie Odero-Marah; Takeo Nomura; Katsumi Shigemura; Tohru Miyagi; Seogil Seo; Chumeng Shi; Joe Molitierno; James M. Elmore; Cynthia Anderson; Shuji Isotani; Magnus Edlund; Chia Ling Hsieh; Ruoxiang Wang; Bahig M. Shehata; Haiyen E. Zhau
International Journal of Radiation Oncology Biology Physics | 2007
Cynthia Anderson; Mary Koshy; Charles A. Staley; Natia Esiashvili; S. Ghavidel; Zach Fowler; Tim Fox; Fabio Esteves; Jerome C. Landry; Karen D. Godette
International Journal of Radiation Oncology Biology Physics | 2011
Virginia Lang Robertson; Cynthia Anderson; Frank G. Keller; Raghuveer Halkar; Michael Goodman; Robert B. Marcus; Natia Esiashvili
Seminars in Radiation Oncology | 2010
Cynthia Anderson; Walter J. Curran
Cancer Research | 2018
Amber Budmark; Michael Catalano; Tyrel Haley; Brady Hicks; Maria Koenen; Thea Patrick; Tyler Larson; Tyler Wagner; Clark Butler; Joshua Feiner; Rebecca Frick; Sierra Haage; James A. Miller; Mackayla Nohr; Dillon Stadlman; Dillon Turner; Sara Husher; Nicholas Woslum; Nathan Stadem; John Dosch; Tyler Fortuna; Chandler Fredrich; Elise Hadley; Brooklynn Oehlerking; Delayna Paulson; Cal Wiese; Paula Mazzer; Tim Mullican; Cynthia Anderson; Mark Larson
International Journal of Radiation Oncology Biology Physics | 2010
Shannon Kahn; Ashesh B. Jani; Scott Edelman; Jerome C. Landry; Karen D. Godette; Cynthia Anderson